Greater efficacy of 15mg/kg TXA versus 10mg/kg TXA in total hip arthroplasty .
Single-dose tranexamic acid for reducing bleeding and transfusions in total hip arthroplasty: A double-blind, randomized controlled trial of different doses
Thromb Res. 2016 May;141:119-23124 patients scheduled for total hip arthroplasty were randomized to one of three groups: a single intravenous dose of 10mg/kg tranexamic acid (TXA); a single intravenous dose of 15mg/kg TXA; or a single intravenous dose of placebo saline. The purpose of this study was to examine and compare efficacy and safety outcomes between groups. While both TXA groups demonstrated a significant reduction in total blood loss, postoperative drainage volume, and hemoglobin drop compared to placebo, total blood loss and postoperative drainage volume was significantly lower in the 15mg/kg group compared to the 10mg/kg. Additionally, only the 15mg/kg group demonstrated a significant reduction in transfusion incidence compared to the placebo group. Thromboembolic events were similar between the three groups.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
